Finance

Lists
4528:TYO
Ono Pharmaceutical Co Ltd
2 389,00 JPY
-0,06%
(-1,50) 1D
18 სექ, 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4528...
Open
2 398 JPY
High
2 405 JPY
Low
2 376 JPY
Mkt. cap
1,19 ტრლ.
Avg. vol.
1,39 მლნ.
Volume
2,46 მლნ.
Dividend
3,35%
Quarterly dividend
20 JPY
Ex-dividend date
29 სექ. 2026
P/E ratio
14,73
52-wk high
2 674 JPY
52-wk low
1 674 JPY
EPS
162 JPY
Shares outstanding
514,12 მლნ.
No. of employees
4 ათ.
Open
2 398 JPY
High
2 405 JPY
Low
2 376 JPY
Mkt. cap
1,19 ტრლ.
Avg. vol.
1,39 მლნ.
Volume
2,46 მლნ.
Dividend
3,35%
Quarterly dividend
20 JPY
Ex-dividend date
29 სექ. 2026
P/E ratio
14,73
52-wk high
2 674 JPY
52-wk low
1 674 JPY
EPS
162 JPY
Shares outstanding
514,12 მლნ.
No. of employees
4 ათ.
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka. Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948. Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen. Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb. In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical Co Ltd
CEOGyo Sagara | Gyo Sagara
Employees4,21 ათ.
Founded1717
Headquartersოსაკა, Osaka, იაპონია
SectorPharmaceutical industry
Last report
31 ივლ. 2026
Fiscal period
Q1 2027
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
116,16 მლრ. / 112,15 მლრ.
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
129,60 მლრ.
139,90 მლრ.
118,75 მლრ.
116,16 მლრ.
Cost of goods sold
34,96 მლრდ.
36,68 მლრდ.
33,06 მლრდ.
28,68 მლრდ.
Cost of revenue
34,96 მლრდ.
36,68 მლრდ.
33,06 მლრდ.
28,68 მლრდ.
Research and development expenses
34,77 მლრდ.
33,53 მლრდ.
42,49 მლრდ.
32,40 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
30,08 მლრდ.
31,73 მლრდ.
27,70 მლრდ.
23,90 მლრდ.
Operating expense
64,56 მლრდ.
67,00 მლრდ.
77,09 მლრდ.
56,83 მლრდ.
Total operating expenses
99,53 მლრდ.
103,68 მლრ.
110,15 მლრ.
85,51 მლრდ.
Operating income
30,07 მლრდ.
36,22 მლრდ.
8,60 მლრდ.
30,65 მლრდ.
Other non operating income
-
-
318,00 მლნ.
-2,00 მლნ.
EBT including unusual items
29,52 მლრდ.
37,20 მლრდ.
3,28 მლრდ.
31,25 მლრდ.
EBT excluding unusual items
29,52 მლრდ.
37,20 მლრდ.
8,77 მლრდ.
31,25 მლრდ.
Income tax expense
7,17 მლრდ.
8,31 მლრდ.
2,24 მლრდ.
7,09 მლრდ.
Effective tax rate
24,30%
22,35%
68,23%
22,68%
Other operating expenses
-291,00 მლნ.
1,73 მლრდ.
3,81 მლრდ.
526,00 მლნ.
Net income
22,42 მლრდ.
28,86 მლრდ.
818,00 მლნ.
24,15 მლრდ.
Net profit margin
17,30%
20,63%
0,69%
20,79%
Earnings per share
-
-
-
-
Interest and investment income
677,00 მლნ.
1,39 მლრდ.
195,00 მლნ.
1,38 მლრდ.
Interest expense
-1,23 მლრდ.
-408,00 მლნ.
-34,00 მლნ.
-783,00 მლნ.
Net interest expenses
-549,00 მლნ.
979,00 მლნ.
161,00 მლნ.
598,00 მლნ.
Depreciation and amortization charges
-
-
3,10 მლრდ.
-
EBITDA
39,39 მლრდ.
45,82 მლრდ.
18,21 მლრდ.
39,63 მლრდ.
Gain or loss from assets sale
-
-
2,20 მლრდ.
-
AI content may include mistakes. Learn more
Google აპები